Abstract
Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patients bedside are in the range of $800 million for each new compound. Innovative preclinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Keywords: 3D cell culture, extracellular matrix, ECM, cellular spheroid, microcarrier culture, microfluidic culture, organotypic culture, drug discovery, toxicity screening, 3R agenda
Recent Patents on Biotechnology
Title: Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Volume: 3 Issue: 2
Author(s): Francesco Pampaloni, Ernst H. K. Stelzer and Andrea Masotti
Affiliation:
Keywords: 3D cell culture, extracellular matrix, ECM, cellular spheroid, microcarrier culture, microfluidic culture, organotypic culture, drug discovery, toxicity screening, 3R agenda
Abstract: Launching a new drug on the market is an extremely time-consuming and expensive process. The total costs from the lab bench to the patients bedside are in the range of $800 million for each new compound. Innovative preclinical assays are urgently needed to select the most promising drug candidates. High-throughput molecular screening does not provide information on the effects on cellular functions. Testing on animals is expensive, ethically controversial, and poorly predictive of the response in humans. Conventional two-dimensional (2D) cellular assays do not accurately reflect the drug response in vivo. To overcome these limitations, biotechnologists are developing three-dimensional (3D) cultures. 3D cultures provide more accurate compound screening and can eliminate toxic and ineffective substances at an early stage. Moreover, 3D cultures can accomplish the 3R agenda (refinement, reduction, and replacement) for the replacement of toxicity testing on animals. We provide an up-to-date overview on the patents in the field.
Export Options
About this article
Cite this article as:
Pampaloni Francesco, Stelzer H. K. Ernst and Masotti Andrea, Three-Dimensional Tissue Models for Drug Discovery and Toxicology, Recent Patents on Biotechnology 2009; 3 (2) . https://dx.doi.org/10.2174/187220809788700201
DOI https://dx.doi.org/10.2174/187220809788700201 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Delineating Characteristic Sequence and Structural Features of Precursor and Mature Piwi-interacting RNAs of Epithelial Ovarian Cancer
Current Bioinformatics Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses
Current Pharmaceutical Design Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Depression has a Strong Relationship to Alterations in the Immune, Endocrine and Neural System
Current Psychiatry Reviews Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Machine Learning and Perturbation Theory Machine Learning (PTML) in Medicinal Chemistry, Biotechnology, and Nanotechnology
Current Topics in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Dequalinium-Derived Nanoconstructs: A Promising Vehicle for Mitochondrial Targeting
Current Drug Delivery The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Circular RNAs and Glioma: Small Molecule with Big Actions
Current Molecular Medicine Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Heat Shock Protein 90 Inhibitors as Broad Spectrum Anti-Infectives
Current Pharmaceutical Design In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Advances in the Chemistry and Pharmacology of Ecteinascidins, A Promising New Class of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry